Patients maintain stable response with no or minimal fluctuations during 3 years of continuous treatment with lebrikizumab during long-term extension trial


Por: Silverberg, J, Gold, LS, Lio, P, del Rosso, J, Wollenberg, A, Carrascosa, JM, Gallo, G, Ding, YX, Agell, H, Diemert, S and Vestergaard, C

Publicada: 1 feb 2026
Resumen:


Filiaciones:
Silverberg, J:
 George Washington Univ, Sch Med & Hlth Sci, George Dept Dermatol, Washington, DC USA

Gold, LS:
 Henry Ford Hlth Syst, Dermatol Clin Res, Detroit, MI USA

Lio, P:
 Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

del Rosso, J:
 JDR Dermatol Res, Las Vegas, NV USA

Wollenberg, A:
 Augsburg Univ Hosp, Dept Dermatol & Allergy, Augsburg, Germany

 Univ Lubeck, Comprehens Ctr Inflammat Med, Lubeck, Germany

:
 Hosp Universitari Germans Trias I Pujol, Dermatol Dept, UAB, IGTP, Badalona, Spain

Gallo, G:
 Eli Lilly & Co, Indianapolis, IN USA

Ding, YX:
 Eli Lilly & Co, Indianapolis, IN USA

Agell, H:
 Almirall, Barcelona, Spain

Diemert, S:
 Almirall Hermal GmbH, Hamburg, Germany

Vestergaard, C:
 Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark
ISSN: 16100379





JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
Editorial
Blackwell Publishing Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Meeting Abstract
Volumen: 24 Número:
Páginas: 17-17
WOS Id: 001716254200051

MÉTRICAS